Trevi Therapeutics raised $150 million through a planned equity offering as it looks to fund pipeline development and clinical progress. The report indicates the company plans to float more than 11.5 million shares at $13 per share, using the proceeds to advance its oncology-focused strategy. The funding update is grouped here as a high-impact capital event because the scale is sufficient to meaningfully extend runway for clinical milestones and partnerships. It also reflects investor willingness to back mid-cap biotech structures when the financing plan aligns with near-to-medium-term data catalysts. While details on specific trial endpoints were not included in the excerpt, the context provided frames the raise as a step in executing a broader company development plan. For biotech professionals tracking risk capital, the Trevi print is a reminder that public-market access remains open for companies that can articulate defined clinical objectives with credible execution schedules.